44 completed. 44 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 44 | Completed 44 |
| Phase 2 | 5 | Completed 5 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) JTE-162 - Cryopyrin-associated Periodic Syndromes (CAPS) | Phase 1 | Completed | Akros Pharma Inc. | 5 | 2026-02-02 | 2026-10-09 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes HRS-3095 Tablet, HRS-3095 Placebo Tablet - Chronic Spontaneous Urticaria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 82 | 2025-11-10 | 2026-06-12 |
| To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions Bilastine oral dispersible tablets, Bilaxten oral dispersible tablets - Allergic Rhino-Conjunctivitis, Urticaria | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 42 | 2025-04-30 | 2025-06-29 |
| Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001 AK006 IV - Chronic Spontaneous Urticaria | Phase 1 | Completed | Allakos Inc. | 29 | 2024-08-28 | 2025-08-27 |
| Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Briquilimab, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Completed | Jasper Therapeutics, Inc. | 87 | 2023-11-29 | 2026-08-06 |
| Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria Oral EP262 - Chronic Inducible Urticaria | Phase 1 | Completed | Escient Pharmaceuticals, Inc | 33 | 2023-08-30 | 2024-12-09 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria AK006-IV, Placebo-IV, AK006-SC - Healthy Participants, Chronic Spontaneous Urticaria | Phase 1 | Completed | Allakos Inc. | 136 | 2023-08-28 | 2025-06-03 |
| A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases YH35324, Omalizumab, Placebo - Allergic Disease, Chronic Spontaneous Urticaria | Phase 1 | Completed | Yuhan Corporation | 30 | 2023-08-23 | 2024-11-22 |
| A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema Navenibart - Hereditary Angioedema | Phase 1 / Phase 2 | Completed | Astria Therapeutics, Inc. | 29 | 2023-02-21 | 2026-05-08 |
| A Study of STAR-0215 in Healthy Adult Participants STAR-0215 (SC), Placebo (SC), STAR-0215 (IV) - Hereditary Angioedema | Phase 1 | Completed | Astria Therapeutics, Inc. | 41 | 2022-07-27 | 2024-01-11 |
| A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants LP-003 Dose 1 (Single), LP-003 Dose 2 (Single), LP-003 Dose 3 (Single) - Chronic Spontaneous Urticaria | Phase 1 | Completed | Longbio Pharma | 60 | 2022-07-13 | 2025-12-12 |
| Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. TLL018 tablets - Chronic Spontaneous Urticaria | Phase 1 | Completed | Hangzhou Highlightll Pharmaceutical Co., Ltd | 41 | 2022-05-10 | 2024-03-01 |
| Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% Fexofenadine Hydrochloride Topical Lotion 1% (OP2101) - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 1 | Completed | OrchestratePharma GmbH | 12 | 2022-04-01 | 2023-03-29 |
| Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults cAd3-Marburg, cAd3-EBO-S - Ebola Virus Disease, Marburg Virus Disease | Phase 1 | Completed | Albert B. Sabin Vaccine Institute | 32 | 2021-01-06 | 2022-08-03 |
| A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria CDX-0159 - Cold Urticaria, Cold Contact Urticaria | Phase 1 | Completed | Celldex Therapeutics | 41 | 2020-11-24 | 2023-05-17 |
| A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria CDX-0159, Normal Saline - Chronic Spontaneous Urticaria | Phase 1 | Completed | Celldex Therapeutics | 45 | 2020-09-24 | 2023-07-19 |
| Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations KVD824 Prototype 1 modified-release tablet, KVD824 Prototype 2 modified-release tablet, KVD824 Immediate-Release Capsule - Hereditary Angioedema | Phase 1 | Completed | KalVista Pharmaceuticals, Ltd. | 37 | 2020-05-19 | 2021-11-12 |
| Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers GNR-038, 25 МЕ/kg, GNR-038, 50 МЕ/kg, GNR-038, 100 МЕ/kg - Hereditary Angioedema | Phase 1 | Completed | AO GENERIUM | 36 | 2020-03-10 | 2020-09-30 |
| Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334 IZD334, Placebos - Healthy Volunteers, Cryopyrin Associated Periodic Syndrome | Phase 1 | Completed | Inflazome UK Ltd | 64 | 2019-09-13 | 2020-03-02 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients UB-221 - Urticaria Chronic | Phase 1 | Completed | United BioPharma | 15 | 2019-04-09 | 2022-05-13 |
Showing 20 of 44. Sign in to see all of them.
Angioedemas, Hereditary (18) · Chronic Urticaria (11) · Hypersensitivity (5) · Pruritus (5) · Angioedema (4) · Cryopyrin-Associated Periodic Syndromes (4) · Immune System Diseases (4) · Rhinitis, Allergic (3) · Skin Diseases (3) · Skin Diseases, Vascular (3) · Cardiovascular Diseases (2) · Chronic Inducible Urticaria (2) · Cold Urticaria (2) · Exanthema (2)
Skin and Connective Tissue Diseases (44) · Hypersensitivity, Immediate (42) · Skin Diseases (41) · Skin Diseases, Vascular (41) · Immune System Diseases (40) · Hypersensitivity (39) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (23) · Genetic Diseases, Inborn (21) · Pathological Conditions, Signs and Symptoms (19) · Cardiovascular Diseases (18) · Hereditary Complement Deficiency Diseases (18) · Immunologic Deficiency Syndromes (18) · Primary Immunodeficiency Diseases (18) · Vascular Diseases (18)
berotralstat (4) · bilastine (3) · Complement C1 Inhibitor Protein (2) · Interleukin 1 Receptor Antagonist Protein (2) · Omalizumab (2) · avoralstat (2) · lanadelumab (2) · Abatacept (1) · Cyclosporine (1) · Digoxin (1) · GSK2646264 (1) · Injections (1) · Ketoconazole (1) · Long-Term Synaptic Depression (1) · Moxifloxacin (1)
BioCryst Pharmaceuticals (6) · Shire (5) · KalVista Pharmaceuticals, Ltd. (3) · AO GENERIUM (2) · Allakos Inc. (2) · Astria Therapeutics, Inc. (2) · CSL Behring (2) · Celldex Therapeutics (2) · Faes Farma, S.A. (2) · Akros Pharma Inc. (1) · Albert B. Sabin Vaccine Institute (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Escient Pharmaceuticals, Inc (1) · GlaxoSmithKline (1) · Handok Inc. (1)
United States (16) · United Kingdom (11) · Germany (9) · Canada (6) · China (3) · South Korea (3) · Australia (2) · Russia (2) · Bangladesh (1) · Bulgaria (1) · Czechia (1) · France (1) · India (1) · Italy (1) · Jordan (1)
Joanne Collier, MBChB, FFPM, Dip Stats (OU) (2) · Clifton O. Bingham, M.D. (1) · David Hoover, MD (1) · Firas Almazedi, MBChB, Msc, CPI (1) · Gunilla Hedlin, Prof. Dr. (1) · Hae-Sim Park (1) · Hyeong Ki Lee, Professor (1) · Jason Lickliter, MBBS, PhD (1) · Joanne Collier (1) · Lennart Nordvall, Prof. Dr (1)
PMID 1538192, PMID 15577929, PMID 16375711, PMID 21642470, PMID 22393898, PMID 24105252, PMID 24980392, PMID 25426834, PMID 26016741, PMID 28225674, PMID 34020509, PMID 35086692, PMID 40158724, PMID 41794053, PMID 8237108
2009 (1), 2014 (1), 2023 (1)